Healthcare & Pharmaceutical Market Research in Singapore

BioNixus is a leading healthcare market research company in Singapore, delivering HBRA-compliant HCP surveys, KOL mapping, and payer landscape research aligned with HSA, ACE, and MOH requirements. BioNixus combines primary research depth with physician access across Singapore's public healthcare clusters — SingHealth, NUHS, and NHG — as well as private specialist networks.

A healthcare market research company in Singapore designs and executes studies covering physician prescribing behaviour, payer and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Singapore market and across the wider APAC region.

Singapore's system is government-subsidy-driven and centrally coordinated by the Ministry of Health (MOH). HSA approval does not guarantee market access — commercial outcomes depend on ACE (Agency for Care Effectiveness) health technology and cost-effectiveness assessments, MOH drug subsidy listing decisions via the Standard Drug List (SDL) and Medication Assistance Fund (MAF), and procurement through ALPS (Agency for Logistics & Procurement Services) group purchasing across the public clusters. National financing schemes — MediShield Life, MediSave, MediFund, and CHAS — shape patient affordability and uptake.

BioNixus covers oncology, immunology and biologics (including biosimilar adoption), cardiovascular, diabetes and metabolic (including GLP-1, a national priority given the War on Diabetes), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Singapore market.

Yes. BioNixus maintains physician and specialist networks across Singapore's major academic medical centres and public hospitals including Singapore General Hospital (SGH), National University Hospital (NUH), Tan Tock Seng Hospital (TTSH), and the National Cancer Centre Singapore (NCCS). For scarce specialties such as oncology or rare disease, we recruit through national centre networks and academic faculty at NUS Yong Loo Lin School of Medicine, Duke-NUS Medical School, and NTU LKCMedicine.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, IRB/DSRB review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across the public clusters may require extended planning timelines.

Yes. BioNixus designs and executes Singapore patient research in compliance with the Personal Data Protection Act (PDPA) and Human Biomedical Research Act (HBRA) research ethics requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, IRB/DSRB review where applicable, and secure data handling consistent with Singapore privacy legislation.

Yes. Singapore modules can run with comparable cells across the wider APAC region as well as the USA, UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner. Singapore frequently serves as the APAC regional hub for these programmes.